Portal de Periódicos da CAPES

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico

2021; Massachusetts Medical Society; Volume: 386; Issue: 6 Linguagem: Inglês

10.1056/nejmoa2116185

1533-4406

Lisa M. Dunkle, Karen L. Kotloff, Cynthia L. Gay, Germán Áñez, Jeffrey Adelglass, Alejandro Quintín Barrat Hernández, Wayne L. Harper, Daniel M. Duncanson, Monica A. McArthur, Diana F. Florescu, R. Scott McClelland, Veronica Garcia-Fragoso, Robert Riesenberg, David B. Musante, David L. Fried, Beth Safirstein, Mark McKenzie, Robert Jeanfreau, Jeffrey K. Kingsley, Jeffrey A. Henderson, Dakotah C. Lane, Guillermo M. Ruiz‐Palacios, Lawrence Corey, Kathleen M. Neuzil, Robert W. Coombs, Alexander L. Greninger, Julia Hütter, Julie A. Ake, Katherine R. Smith, Wayne Woo, Iksung Cho, Gregory M. Glenn, Filip Dubovsky,

COVID-19 Clinical Research Studies

NVX-CoV2373 is an adjuvanted, recombinant spike protein nanoparticle vaccine that was shown to have clinical efficacy for the prevention of coronavirus disease 2019 (Covid-19) in phase 2b–3 trials in the United Kingdom and South Africa, but its efficacy had not yet been tested in North America.